Company: GIFLF
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001104659-25-071915
Chunk: 2

Company: Grifols SA
Filing Date: 2025-07-30
Form: 6-K
Chunk 2
---
RS), and excludes lease payments.                              |

| 3 | Defined as per the Credit 
 Agreement.                |

| 4 | Cash and cash equivalents                                                       
 of €559m + unused credit facilities €1,251m - unused RCF facilities maturing in 
 Nov 2025 c€396m.                                                                |

| 5 | Please refer to 2025                                                       
 Guidance on page 38 of the Capital Markets Day Presentation (27 Feb 2025). |

Page 1 of 5

As part of its capital allocation framework,
Grifols successfully completed the delisting of Biotest from the Frankfurt Stock Exchange and increased its equity stake to 80.32%. This
transaction, with a total cost of EUR 108 million, was fully funded through available financial resources.

The company declared a EUR 0.15 per share dividend
payment supported by continued underlying earnings and free cash flow generation momentum. This reflects the company’s strong commitment
to shareholder returns.

Nacho Abia, CEO of Grifols, said: “The
company’s strong performance in the first six months of 2025 reflects the solid execution of our Value Creation Plan. The momentum
of the business is clear: in a context of strong underlying demand, we continue to capitalize on the strength of our Biopharma business
unit while advancing on key priorities.”

Nacho Abiaadded: “While the value
creation will ultimately benefit our shareholders, we continue to be fully committed to developing solutions that address patients’
needs - a priority that has defined Grifols for more than 116 years.”

Rahul Srinivasan, CFO of Grifols, said:
“The company's strong first-half performance underscores both the attractive fundamentals and resilience of our business. We remain
resolutely focused on leveraging the strengths of our business model and disciplined execution, capitalizing on our underlying momentum
and operational focus to deliver on our deleveraging and free cash-flow generation priorities, whilst reinforcing the strong confidence
in the company’s long-term value.”

On the exposure and potential impact of trade
tariffs, the company is well-prepared, thanks to a locally operated and vertically integrated business model. Since its international
expansion over 30 years ago, Grifols has invested consistently in a global network of donation, processing, and distribution centers
for plasma-derived medicines, allowing it to operate locally in the United States, Europe, Egypt, and Canada. The integration minimizes
the need for imports and/or exports within